Latest:
Dr. Reid on Remaining Challenges Regarding the Management of Immune-Related AEs
Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Monica Janke, MD
Latest:
Virtual Surveillance Visits with Symptom, Serum CA-125 Review May Offer Alternative for Ovarian Cancer Recurrence Detection.
In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.
Qi Cheng, MD
Qi Cheng, MD is a medical doctor at Huazhong University of Science and Technology.
Latest:
Dr Cheng on the Safety and Efficacy of Irpagratinib Plus Atezolizumab in Advanced HCC
Qi Cheng, MD, discusses the safety and efficacy of irpagratinib plus atezolizumab in advanced hepatocellular carcinoma.
Antoinette R. Tan, MD, MHSc
Latest:
Dr. Tan on the Potential of Elacestrant in the EMERALD Trial in ER+ Breast Cancer
Antoinette R. Tan, MD, MHSc, discusses the potential of the oral selective estrogen receptor degrader elacestrant being investigated in the phase 3 EMERALD trial in estrogen receptor–positive breast cancer.
Baptist Health Cancer Center
Latest:
Baptist Health Miami Cancer Institute Celebrates 1000th Patient Treated Using Gamma Knife
Baptist Health Miami Cancer Institute treated its 1000th patient using Gamma Knife radiosurgery, an incisionless radiation therapy that precisely targets a tumor, importantly minimizing damage to otherwise healthy brain tissue.
Seema A. Khan, MD
Latest:
Dr Khan on Optimizing Local Therapy Using MRI and a 12-Gene Expression Assay in DCIS
Seema A. Khan, MD, discusses 5-year clinical outcomes from the ECOG-ACRIN E4112 trial, which is evaluating the use of MRI and a 12-gene expression assay to optimize local therapy for patients with ductal carcinoma in situ.
Bisiayo Fashemi, PhD
Latest:
Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models
Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.
Christian Fidler, MD
Latest:
Practice Pearls for Treatment of Secondary AML in the Community Setting
Panelists discuss how treating secondary AML in the community setting requires a multifaceted approach, emphasizing early diagnosis, risk stratification, timely referral when necessary, and close collaboration with academic centers to provide optimal patient care.
Arpita P. Gandhi, MD
Latest:
Unanswered Questions and the Future for Orca-T: What’s Next?
Panelists discuss how unanswered questions regarding long-term outcomes and potential late toxicities, along with the need for further evaluation in specific patient subgroups, highlight the importance of continued research to refine the use of Orca-T across diverse populations.
Neal S. Akhave, MD
Neal S. Akhave, MD, is an assistant Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
Latest:
Exploring NCCN Guideline Updates and Advancing Immunotherapy Strategies in Nasopharyngeal Carcinoma: With Neal S. Akhave, MD
Neal S. Akhave, MD, discusses the addition of toripalimab to the NCCN guidelines for nasopharyngeal carcinoma.